 Home > Medical News > Medical World News > Type 1 diabetes research drug TTP399 was awarded the title of breakthrough therapy by FDA

Type 1 diabetes research drug TTP399 was awarded the title of breakthrough therapy by FDA

 Last Update: 2021-05-02
 Source: Internet
 Author: User

Tags

cbd drug interactions

amlexanox weight loss

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

CompileKe Ke

On April 13, the US FDA granted vTv Therapeutics' research drug TTP399 the title of breakthrough therapy for type 1 diabetes (T1D).

It is reported that TTP399 is an adjuvant therapy for insulin treatment of type 1 diabetes.

The award of the breakthrough therapy title is based on the latest positive data from the Phase II clinical study SimpliciT-1, a multi-center, randomized, double-blind, adaptive study that evaluates TTP399 as an adjuvant insulin therapy in the treatment of adult T1D patients.

Data show that compared with placebo, after treatment with 800mg TTP399, the patient's glycosylated hemoglobin (HbA1c) level was statistically significantly reduced; the incidence of severe or symptomatic hypoglycemia (low blood sugar level) was also clinically reduced About 40%.

T1D is an autoimmune disease.

Reference source: FDA Grants vTv's Type 1 Diabetes Drug Breakthrough Therapy Designation

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Type 1 diabetes research drug TTP399 was awarded the title of breakthrough therapy by FDA

07-10

Related Products

High Quality Pharmaceutical Intermediate API Raw Material 3,4-difluoro- CAS 2396750-32-4

CAS No.: 2396750-32-4

Industrial Grade

$700.00/G EXW

4,4,5,5-Tetramethyl-2-(8-phenyl-2-naphthalenyl)-1,3,2-dioxaborolane / 2417084-74-1

CAS No.: 2417084-74-1

Chemical Grade

$10/KG FOB

6-Azauracil

CAS No.: 461-89-2

Pharmacy Grade

$255-310/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Type 1 diabetes research drug TTP399 was awarded the title of breakthrough therapy by FDA

Related Articles

Type 1 diabetes research drug TTP399 was awarded the title of breakthrough therapy by FDA